中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
24期
3725-3726
,共2页
肝损害%肝炎,乙型,慢性%谷胱甘肽%他汀类药物
肝損害%肝炎,乙型,慢性%穀胱甘肽%他汀類藥物
간손해%간염,을형,만성%곡광감태%타정류약물
Hepatic involvement%Hepatitis B,chronic%Glutathione%Statin
目的 观察谷胱甘肽(GSH)对他汀类药物致乙型肝炎标志物阳性患者肝损害的预防作用.方法 采用他汀类药物治疗的乙型肝炎标志物阳性患者164例随机分为治疗组(82例)和对照组(82例),在应用他汀类药物治疗原发病的同时,对照组采用基础护肝治疗(给予肌苷、维生素C等治疗),治疗组采用还原型谷胱甘肽静脉滴注(1.2g/次,1次/d).分别于治疗前、治疗后12周检测患者肝功能指标.结果 对照组治疗后丙氨酸氨基转移酶、总胆红素、直接胆红素水平较治疗前明显升高(t=2.66、1.98、2.13,均P＜0.05);治疗组治疗前后各项观察指标水平差异均无统计学意义(均P＞0.05),治疗组治疗后丙氨酸氨基转移酶超过正常值12例(14.6％)、＞3倍正常值上限0例,对照组分别为23例(28.1％)、3例(3.7％),两组差异均有统计学意义(x2=4.672,5.304,均P＜0.05).结论 还原型谷胱甘肽可明显减少他汀类药物致乙型肝炎标志物阳性患者肝损害的发生.
目的 觀察穀胱甘肽(GSH)對他汀類藥物緻乙型肝炎標誌物暘性患者肝損害的預防作用.方法 採用他汀類藥物治療的乙型肝炎標誌物暘性患者164例隨機分為治療組(82例)和對照組(82例),在應用他汀類藥物治療原髮病的同時,對照組採用基礎護肝治療(給予肌苷、維生素C等治療),治療組採用還原型穀胱甘肽靜脈滴註(1.2g/次,1次/d).分彆于治療前、治療後12週檢測患者肝功能指標.結果 對照組治療後丙氨痠氨基轉移酶、總膽紅素、直接膽紅素水平較治療前明顯升高(t=2.66、1.98、2.13,均P＜0.05);治療組治療前後各項觀察指標水平差異均無統計學意義(均P＞0.05),治療組治療後丙氨痠氨基轉移酶超過正常值12例(14.6％)、＞3倍正常值上限0例,對照組分彆為23例(28.1％)、3例(3.7％),兩組差異均有統計學意義(x2=4.672,5.304,均P＜0.05).結論 還原型穀胱甘肽可明顯減少他汀類藥物緻乙型肝炎標誌物暘性患者肝損害的髮生.
목적 관찰곡광감태(GSH)대타정류약물치을형간염표지물양성환자간손해적예방작용.방법 채용타정류약물치료적을형간염표지물양성환자164례수궤분위치료조(82례)화대조조(82례),재응용타정류약물치료원발병적동시,대조조채용기출호간치료(급여기감、유생소C등치료),치료조채용환원형곡광감태정맥적주(1.2g/차,1차/d).분별우치료전、치료후12주검측환자간공능지표.결과 대조조치료후병안산안기전이매、총담홍소、직접담홍소수평교치료전명현승고(t=2.66、1.98、2.13,균P＜0.05);치료조치료전후각항관찰지표수평차이균무통계학의의(균P＞0.05),치료조치료후병안산안기전이매초과정상치12례(14.6％)、＞3배정상치상한0례,대조조분별위23례(28.1％)、3례(3.7％),량조차이균유통계학의의(x2=4.672,5.304,균P＜0.05).결론 환원형곡광감태가명현감소타정류약물치을형간염표지물양성환자간손해적발생.
Objective To observe the clinical efficacy of glutathione(GSH)to reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.Methods 164 cases with hepatitis B markers positive were selected and divided into the treatment group(82 cases)and control group(82 cases).In a statin therapy with primary disease,at the same time,the control group using based protect liver therapy(both inosine,vitamin C),the treatment group using reduced glutathione intravenous drip(1.2g,one/d).After 12 weeks,the liver function was examined.Results Patients taking statins ALT,TB and DB levels obviously higher than before,had a statistically significant difference(t=2.66,1.98,2.13,P＜0.05),the differences of observation index level in treatment group before and after treatment had no statistical difference(P＞0.05),12 patients(14.6％)ALT level in treatment group were more than normal,0 case more than normal limit 3 times,control group respectively for 23 cases(28.1％),3 cases(3.7％),two groups had statistically significant difference(x2=4.672,5.304,all P＜0.05).Conclusion GSH can obviously reduce hepatic involvement of statin therapy patients with hepatitis B markers positive.
